Vanguard Capital Management
NNVC icon

Vanguard Capital Management’s NanoViricides NNVC Stock Holding History

Vanguard Capital Management’s Portfolio NNVC Stock Details NNVC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.2M Hold
919,313
– – ﹤0.01% 3513
2026
Q2 		$1.27M Buy
919,313
+407,836
+80% +$559K ﹤0.01% 3543
2026
Q1 		$466K Buy
+511,477
New +$535K ﹤0.01% 3684

Other funds holding NNVC

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Miller Financial Services
Miller Financial Services Marshall, Michigan $132M AUM 10.64% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Empowered Funds
Empowered Funds Havertown, Pennsylvania $21.7B AUM 41.23% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.87B AUM 19.94% 1-Year Est. Return

Vanguard Capital Management's NNVC Position: Q3 2026 in Review

Vanguard Capital Management held its NanoViricides (NNVC) position steady in Q3 2026 at 919,313 shares worth $1.2M. The position accounts for ﹤0.01% of the portfolio, ranked #3513.

Vanguard Capital Management first reported a position in NNVC in Q1 2026 and has held it in 3 quarters since. The position peaked at $1.27M in Q2 2026. 38 funds tracked by Wall St. Rank hold NNVC as of Q3 2026.

  • Vanguard Capital Management held 919,313 shares of NanoViricides worth $1.2M as of Q3 2026.
  • Vanguard Capital Management left its NanoViricides share count unchanged in Q3 2026.
  • NanoViricides made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #3513 holding.
  • Vanguard Capital Management first reported a position in NanoViricides in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Capital Management's NanoViricides position peaked at $1.27M in Q2 2026.
  • 38 funds tracked by Wall St. Rank held NanoViricides as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.